子宫内膜异位症相关卵巢中肾样腺癌9例临床病理分析
收集2022年1月至2024年12月复旦大学附属妇产科医院9例EM相关卵巢MLA患者资料,复核病理切片并行免疫组化及分子检测。肿瘤形态多样且常混合其他肿瘤,KRAS突变5/5,手术为主术后辅以化疗,随访期内3例复发、无死亡。
要点
- EM相关卵巢MLA形态多样,常与内膜样癌、交界性肿瘤等其他成分共存。
- 诊断依赖组织形态学、免疫组化及分子检测综合评估,KRAS突变5/5。
- 治疗以手术为主、术后辅以化疗;随访期内3例复发、无死亡。
核心结论
- EM相关卵巢MLA具有多种形态学表现,常混合其他类型肿瘤,准确诊断依赖组织形态学、免疫组化及分子检测的综合评估。
- 治疗以手术为主,术后辅以化疗,伴有KRAS基因p.G12C致病性突变患者可能靶向治疗有效。
- 肿瘤具有侵袭性,短期内易复发,预后较差。
研究设计与样本
- 收集2022年1月至2024年12月复旦大学附属妇产科医院收治的9例EM相关卵巢MLA患者的临床病理资料。
- 复核病理切片,行免疫组化检测及分子检测并进行随访。
主要发现
- 9例患者中位年龄54岁(范围38~69岁),均表现为盆腔包块,其中5例伴腹痛。
- 肿瘤位于右侧卵巢5例、左侧卵巢2例、双侧卵巢2例;FIGO分期Ⅰ期3例、Ⅱ期4例、Ⅲ期2例。
- 中位肿瘤最大径9.0 cm(范围2.6~13.0 cm);9例共11个病灶,其中8个病灶为MLA与其他类型肿瘤共存。
- 免疫组化GATA结合蛋白3、甲状腺转录因子1、CD10、钙视网膜蛋白阳性表达率分别为9/11、8/11、5/11及3/6;11个病灶p53均呈野生型表达。
- 5例行二代测序均检测到KRAS基因致病性突变(5/5),其中3例(3/5)合并其他基因致病性突变。
关键数值与推荐
- 9例患者中5例行全面分期手术,4例行肿瘤细胞减灭术;1例KRAS基因p.G12C致病性突变患者行靶向治疗。
- 中位随访时间7个月(范围2~27个月),随访期内3例复发(复发率3/9),无患者死亡。
临床怎么用
- 卵巢MLA的治疗以手术为主,辅以化疗和(或)靶向治疗。
- 伴有KRAS基因p.G12C致病性突变患者可能靶向治疗有效(作者结论)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the clinical and pathological characteristics, treatment and prognosis of endometriosis (EM)-associated ovarian mesonephric-like adenocarcinoma (MLA). Methods: Clinical and pathological data were collected from nine patients diagnosed with EM-associated ovarian MLA at the Obstetrics and Gynecology Hospital of Fudan University between January 2022 and December 2024. Histological slides were re-reviewed, immunohistochemical examination and molecular testing were performed, and patient follow-up was conducted. Results: (1) Clinical characteristics: the median age of the nine patients was 54 years (range: 38-69 years). All patients presented with a pelvic mass; five cases also reported abdominal pain. Tumor location included five cases in the right ovary, two in the left ovary, and two involving both ovaries. International Federation of Gynecology and Obstetrics (FIGO) staging showed 3 cases at stage Ⅰ, 4 at stage Ⅱ, and 2 at stage Ⅲ. (2) Pathological features: gross examination revealed mixed solid-cystic masses with solid areas appearing gray-white or yellow-brown; the median maximum tumor diameter was 9.0 cm (range: 2.6-13.0 cm). Microscopically, tumors exhibited various architectural patterns, including tubular, glandular, papillary, slit-like, sex cord-like, glomeruloid, and solid structures, with tubular and glandular patterns being most common. Tumor cells demonstrated mild to moderate nuclear atypia. Of the 11 tumor foci in the 9 cases, 8 showed coexistence of MLA with other tumor components, such as endometrioid carcinoma, borderline endometrioid or borderline seromucinous tumors. In 1 case of MLA mixed with a borderline endometrioid tumor, both components exhibited squamous metaplasia. Immunohistochemistry showed variable expression of GATA-binding protein 3, thyroid transcription factor-1, CD10, and calretinin, with positive rates of 9/11, 8/11, 5/11, and 3/6, respectively. Two tumor foci (2/11) exhibited focal expression of estrogen receptor and progesterone receptor. All cases displayed wild-type p53 expression. Molecular testing via next-generation sequencing in five patients revealed pathogenic mutations in the KRAS gene (5/5), with 3 cases (3/5) harboring additional pathogenic mutations in other genes. (3) Treatment and prognosis: all patients underwent surgery, supplemented by chemotherapy and (or) targeted therapy. Five patients underwent comprehensive staging surgery, four received cytoreductive surgery, and one patient received targeted therapy. The median follow-up duration was 7 months (range: 2-27 months). Three patients (3/9) experienced recurrence, and no deaths were reported during the follow-up period. Conclusions: EM-associated ovarian MLA demonstrates diverse morphological patterns and frequently coexists with other tumor types. Accurate diagnosis relies on an integrated evaluation of histomorphology, immunohistochemistry, and molecular testing. The primary treatment for EM-associated ovarian MLA is surgery, followed by adjuvant chemotherapy. Patients harboring pathogenic KRAS p.G12C mutations may benefit from targeted therapies. Ovarian MLA is an aggressive tumor, prone to recurrence in the short term, and has a poor prognosis. 目的: 探讨子宫内膜异位症(EM)相关的卵巢中肾样腺癌(MLA)的临床病理特征、治疗及预后。 方法: 收集2022年1月至2024年12月复旦大学附属妇产科医院收治的9例EM相关的卵巢MLA患者,查阅临床病理资料、复核病理切片、行免疫组化检测及分子检测并进行随访。 结果: (1)临床特征:9例患者的中位年龄为54岁(范围:38~69岁);临床症状:9例患者均表现为盆腔包块,其中5例同时伴有腹痛;肿瘤部位:位于右侧卵巢5例,左侧卵巢2例,双侧卵巢2例;国际妇产科联盟(FIGO)分期:Ⅰ期3例,Ⅱ期4例,Ⅲ期2例。(2)病理特征:大体检查,9例患者的肿瘤均表现为囊实性,实性区切面呈灰白色或黄褐色,周围的囊性区为卵巢EM囊肿;中位肿瘤最大径为9.0 cm(范围:2.6~13.0 cm)。镜下观察,肿瘤显示多种生长方式,包括管状、腺状、乳头状、裂隙状、性索样、肾小球样和实性结构等,以管状和腺状结构多见;肿瘤细胞呈轻~中度异型性。9例患者共有11个病灶,其中8个病灶为MLA与其他类型的肿瘤(包括内膜样癌、交界性内膜样肿瘤、交界性浆黏液性肿瘤等)共存,包括1个MLA混合交界性内膜样肿瘤病灶的两种肿瘤成分均伴有鳞化。免疫组化检测显示,卵巢MLA不同程度表达GATA结合蛋白3、甲状腺转录因子1、CD10、钙视网膜蛋白,阳性表达率分别为9/11、8/11、5/11及3/6;2个(2/11)病灶雌激素受体、孕激素受体呈局灶阳性表达,11个(11/11)病灶p53均呈野生型表达。分子检测显示,9例患者中5例行二代测序技术检测,均检测到KRAS基因的致病性突变(5/5),其中3例(3/5)合并其他基因的致病性突变。(3)治疗及预后:卵巢MLA的治疗以手术为主,辅以化疗和(或)靶向治疗。9例患者中,5例行全面分期手术,4例行肿瘤细胞减灭术;1例KRAS基因p.G12C致病性突变患者行靶向治疗。中位随访时间为7个月(范围:2~27个月),随访期内3例复发,复发率为3/9;随访期内无患者死亡。 结论: EM相关的卵巢MLA具有多种形态学表现,常混合其他类型肿瘤,准确诊断MLA依赖于组织形态学检查、免疫组化检测及分子检测的综合评估。EM相关的卵巢MLA的治疗以手术为主,术后辅以化疗,伴有KRAS基因p.G12C致病性突变患者可能靶向治疗有效;肿瘤具有侵袭性,短期内易复发,预后较差。.
引用
- Wang H, Liu J, Cheng Y, et al. [Endometriosis-associated ovarian mesonephric-like adenocarcinoma:a clinicopathological analysis of 9 cases]. Zhonghua Fu Chan Ke Za Zhi. 2025. PMID: 40582970. doi:10.3760/cma.j.cn112141-20241217-00675
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。